The Q1 print is directionless for the stock — the wider loss was expected given the pre-NDA spending ramp. The only catalyst that matters is the mid-2026 NDA submission for ALXN1840. Monitor for FDA acceptance and any PDUFA date assignment; the stock will move on regulatory milestones, not quarterly financials.
Price Chart
Executive Summary
Monopar Therapeutics reported Q1 2026 net loss of $3.9M ($0.46/share), wider than the $2.6M ($0.38/share) loss in Q1 2025, driven by increased R&D spending as the company advances ALXN1840 toward a mid-2026 NDA submission. Cash burn accelerated to $2.9M/quarter from $0.6M/quarter YoY, though the $137.5M cash runway extends through at least December 2027. The NDA timeline remains on track, but the widening loss and lack of revenue keep this a binary catalyst story.
Key Financial Metrics
Key Facts
- Net loss Q1 2026: $3.9M ($0.46/share) vs $2.6M ($0.38/share) Q1 2025
- Cash, cash equivalents and investments: $137.5M as of March 31, 2026
- Cash runway extends through at least December 31, 2027
- R&D expenses increased 112% YoY to $3.49M from $1.64M
- ALXN1840 NDA submission remains on track for mid-2026
- Interest income doubled to $1.33M from $0.60M YoY on $91.9M capital raise proceeds
- No revenue generated — pre-commercial clinical-stage biopharma
Financial Impact
Net loss widened by $1.3M YoY; cash burn rate increased to ~$2.9M/quarter from ~$0.6M/quarter
Risk Factors
- NDA submission delay or FDA rejection of ALXN1840 would be catastrophic for the stock
- Cash burn is accelerating as commercial readiness activities ramp up
- No approved products or revenue — binary regulatory risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-016981 |
| Exhibit: ex_962976.htm | 0001437749-26-016981 |
| Document: 0001437749-26-016981-index-headers.html | 0001437749-26-016981 |
| Document: 0001437749-26-016981-index.html | 0001437749-26-016981 |
| Document: 0001437749-26-016981.txt | 0001437749-26-016981 |
| 8-K Data (Synthetic) | 0001437749-26-016981 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | Institutional Cluster | $72.00 | awaiting T+60 | — | $70.54 (−2.03%) |
Oct 27, 2026 today | SC 13G | $72.00 | awaiting T+60 | — | $70.54 (−2.03%) |
Oct 5, 2026 22d ago | Insider Cluster | $79.57 | awaiting T+60 | — | $70.54 (+11.35%) |
Oct 1, 2026 26d ago | 144 | $77.97 | awaiting T+60 | — | $70.54 (−9.53%) |
Aug 28, 2026 8w ago | Insider Cluster | $111.93 | awaiting T+60 | — | $70.54 (−36.98%) |
Aug 27, 2026 8w ago | Insider Cluster | $111.89 | awaiting T+60 | — | $70.54 (−36.96%) |
Aug 25, 2026 9w ago | 144 | $113.72 | awaiting T+60 | — | $70.54 (−37.97%) |
Aug 12, 2026 10w ago | 8-K | $114.90 | awaiting T+60 | — | $70.54 (−38.61%) |
Aug 12, 2026 10w ago | Press Release | $114.90 | awaiting T+60 | — | $70.54 (−38.61%) |
Jul 22, 2026 13w ago | 8-K | $112.48 $71.80 | ▼ −36.17% | ▼ −39.43% | $70.54 (−37.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers